Log in to save to my catalogue

Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide sec...

Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide sec...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a07626c82ec8444ab56a35322801927a

Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial

About this item

Full title

Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial

Publisher

England: BioMed Central Ltd

Journal title

Current controlled trials in cardiovascular medicine, 2022-01, Vol.23 (1), p.57-16, Article 57

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Glioblastoma is the most frequent and malignant primary brain tumor. Even in the subgroup with O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and favorable response to first-line therapy, survival after relapse is short (12 months). Standard therapy for recurrent MGMT-methylated glioblastoma is not standardized and may consist...

Alternative Titles

Full title

Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_a07626c82ec8444ab56a35322801927a

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a07626c82ec8444ab56a35322801927a

Other Identifiers

ISSN

1745-6215

E-ISSN

1745-6215

DOI

10.1186/s13063-021-05977-0

How to access this item